Short answer
ResMed (RMD) filed an 8-K current report with the SEC on April 30, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). CFO Brett Sandercock retires May 4, 2026, with no reported disagreements over operations, policies, or practices.
ResMed 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- CFO Brett Sandercock retires May 4, 2026, with no reported disagreements over operations, policies, or practices
- Sandercock remains Special Advisor through December 31, 2027, retaining salary, benefits, and equity vesting
- Aaron Bloomer, age 40, appointed CFO, Principal Financial Officer, and Principal Accounting Officer effective May 4, 2026
- Bloomer compensation includes $725,000 salary, 80% incentive target, $3.3 million sign-on equity grant, and $3.3 million fiscal 2027 grant eligibility
- CFO transition preserves continuity but creates substantial retention and onboarding commitments tied to long-term equity performance
Item EX-99.1 · Exhibit EX-99.1
- CFO Brett Sandercock retiring May 4, 2026 after 27 years, including 20 years as CFO
- Aaron Bloomer appointed successor, bringing finance leadership from Exact Sciences, Baxter International and 3M
- Sandercock remains CEO advisor through calendar year 2027, supporting transition continuity
- Fiscal 2026 outlook reiterated: gross margin 62–63%, SG&A 19–20%, R&D 6–7%, effective tax rate 21–23%
- Incoming CFO’s background in margin expansion, capital allocation and M&A supports ResMed’s 2030 strategy execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ResMed 8-K filings
Get the next RMD 8-K as it lands
Follow RMD for push alerts, or ask the research agent what this filing means.